Correct Answer: C. Rifampicin
Rifampicin is a bacterial RNA polymerase inhibitor that specifically blocks the initiation of RNA synthesis in prokaryotes. It binds to the β-subunit of bacterial RNA polymerase, preventing the formation of the first phosphodiester bond and thus inhibiting transcription at the promoter stage. This mechanism makes it highly selective for bacterial cells while sparing eukaryotic RNA polymerases, which have structurally different binding sites. In India, rifampicin is a cornerstone of RNTCP (Revised National Tuberculosis Control Programme) regimens, used as a first-line agent for tuberculosis. It is bactericidal against Mycobacterium tuberculosis and also covers Mycobacterium leprae in leprosy treatment protocols. The drug's ability to inhibit RNA synthesis directly translates to its antimicrobial efficacy—without RNA, bacteria cannot synthesize proteins or replicate. This is the defining pharmacological property that distinguishes rifampicin from other antimicrobials in the question.
Why the other options are wrong
A. 5-Fluorouracil — 5-FU is an antimetabolite that inhibits DNA synthesis, not RNA synthesis. It is a pyrimidine analog that gets converted to active metabolites (FdUMP, FdUTP) that inhibit thymidylate synthase and get incorporated into DNA, making it a chemotherapy agent for cancers, not an RNA synthesis inhibitor. NBE trap: students may confuse nucleotide synthesis inhibitors with RNA synthesis inhibitors. B. Novobiocin — Novobiocin is a DNA gyrase inhibitor (topoisomerase II inhibitor) used against gram-positive bacteria. It prevents DNA supercoiling and replication, not RNA synthesis. It is rarely used clinically in India due to poor bioavailability and toxicity. NBE trap: students may incorrectly group all bacterial transcription/replication inhibitors together without distinguishing the specific target. D. Nitrofurantoin — Nitrofurantoin is a DNA-damaging agent that generates reactive oxygen species and causes DNA strand breaks in bacteria. It is used as a urinary antiseptic for uncomplicated UTIs in India, but its mechanism is DNA damage, not RNA synthesis inhibition. NBE trap: students may confuse antimicrobial mechanisms by grouping all agents that inhibit bacterial replication without distinguishing the molecular target.
High-Yield Facts
- Rifampicin binds to bacterial β-subunit of RNA polymerase and inhibits RNA synthesis initiation, not elongation.
- Rifampicin is bactericidal against Mycobacterium tuberculosis and is a first-line agent in all RNTCP TB regimens in India.
- 5-FU inhibits DNA synthesis (thymidylate synthase inhibitor), Novobiocin inhibits DNA gyrase, Nitrofurantoin causes DNA damage—none inhibit RNA synthesis.
- Rifampicin resistance in TB emerges via mutations in the rpoB gene (RNA polymerase β-subunit), making it a critical surveillance marker in India.
- Rifampicin has high lipophilicity and excellent tissue penetration, including into the CNS, making it ideal for TB meningitis in Indian clinical practice.
Mnemonics
RNA Synthesis Inhibitors (Prokaryotes) RIFampicin = RNA synthesis inhibitor. Remember: Rif = RNA. Rifampicin is the ONLY common bacterial RNA polymerase inhibitor in clinical use; others like lipiarmycin are experimental. Mechanism Sorting: Rif vs Others Rif = RNA polymerase | 5-FU = Thymidylate synthase (DNA) | Novo = DNA gyrase | Nitro = DNA damage. Use this to eliminate wrong options quickly in MCQs.
NBE Trap
NBE pairs rifampicin with other antimicrobials that affect bacterial replication (DNA synthesis, DNA damage) to test whether students understand the specific molecular target. The trap is grouping all "replication inhibitors" together without distinguishing RNA vs. DNA synthesis.
Clinical Pearl
In Indian TB clinics, rifampicin's ability to inhibit RNA synthesis makes it bactericidal even in the first 2 weeks of RNTCP therapy—this rapid bacterial killing is why directly observed therapy (DOT) with rifampicin-containing regimens achieves >95% cure rates in India. Resistance surveillance via rpoB sequencing is now routine in NTEP (National TB Elimination Programme) centers.
_Reference: KD Tripathi Pharmacology Ch. 47 (Antimycobacterial Drugs); Harrison Ch. 163 (Tuberculosis); Jawetz Microbiology Ch. 12 (Antimicrobial Drugs)_